Vanguard Group Inc Corbus Pharmaceuticals Holdings, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.11 - $5.46 $258 - $12,814	2,347 Added 0.06%	4,049,102 $445,000
Q3 2022 Nov 14, 2022	SELL	$0.17 - $5.31 $41,719 - $1.3 Million	-245,408 Reduced 5.72%	4,046,755 $668,000
Q1 2022 May 13, 2022	SELL	$0.32 - $0.67 $355,871 - $745,104	-1,112,097 Reduced 20.58%	4,292,163 $2.28 Million
Q4 2021 Feb 14, 2022	SELL	$0.6 - $1.11 $37,548 - $69,464	-62,581 Reduced 1.14%	5,404,260 $3.33 Million
Q3 2021 Nov 12, 2021	BUY	$1.01 - $1.82 $4,838 - $8,719	4,791 Added 0.09%	5,466,841 $5.58 Million
Q2 2021 Aug 13, 2021	BUY	$1.39 - $2.21 $7.59 Million - $12.1 Million	5,462,050 New	5,462,050 $10 Million

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $1.22B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.